"Centre de traitement du cancer à Lille (Radiothérapie - Chimiothérapie)"

During the past decade, Centre Bourgogne conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 4 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Bourgogne" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Centre Oscar Lambret" with 3 trials sponsored, "Federation Francophone de Cancerologie Digestive" with 1 trials sponsored, "GERCOR - Multidisciplinary Oncology Cooperative Group" with 1 trials sponsored and "Swiss Group for Clinical Cancer Research" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Bourgogne" #1 collaborator was "Aix Marseille Université" with 1 trials as a collaborator, "Canceropôle Nord Ouest" with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator, "National Cancer Institute, France" with 1 trials as a collaborator and "SIRIC ONCOLille" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Centre Bourgogne" are "Breast Cancer" (5 trials), "Breast Neoplasms" (2 trials), "Colorectal Cancer" (2 trials), "Adenocarcinoma of the Gastroesophageal Junction" (1 trials) and "Aging" (1 trials). Many other conditions were trialed in "Centre Bourgogne" in a lesser frequency.

Most popular intervention types in "Centre Bourgogne" are "Drug" (9 trials), "Biological" (3 trials), "Radiation" (3 trials), "Procedure" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Trastuzumab" (4 trials), "Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)" (1 trials), "Capecitabine" (1 trials), "Cetuximab" (1 trials) and "Delivery of questionnaires" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre Bourgogne" are 10 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Centre Bourgogne". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Centre Bourgogne, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Bourgogne, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".